To gain insight in the neurobiological mechanisms behind oxytocin effects on human social-emotional behaviour.
ID
Source
Brief title
Condition
- Other condition
Synonym
Health condition
geen, fundamenteel onderzoek
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Differences in blood oxygen level dependent (BOLD) response between OT
administration and placebo will be measured.
Secondary outcome
2 questionaires
Background summary
Extensive animal literature point to a pivotal role of oxytocin in
social-emotional behaviour in evolutionary distant species. This leads to the
prediction that these peptides which mechnisms are at least partly conserved in
humans still exert its functions in human social-emotional behaviour. An
important question is to what amount these mechanisms play a role in humans. By
applying oxytocin administration together with neuro-imaging we try to unravel
the underlying neurobiological mechanisms in humans.
Study objective
To gain insight in the neurobiological mechanisms behind oxytocin effects on
human social-emotional behaviour.
Study design
A within subjects, double blind placebo controlled OT administration study.
Intervention
The participants will self administer nasal OT spray and placebo on two
separate days. The order of administration (e.g. OT on the first day/ placebo
on the second day) will be counterbalanced.
Study burden and risks
Administration of OT is not known to lead to any adverse side-effects as shown
in previous studies (e.g. Kosfeld et al., 2005), so it is unlikely that our
participants will experience adverse phenomenological alterations. FMRI is a
non-invasive technique, so there is no need for special preparation for the
subject. There are no known risks associated with fMRI acquisition. If
pathology is noticed, and medical treatment is indicated, the subject will be
notified. The benefit of the present experiment is increased understanding of
underlying neurobiological mechanisms of human social emotional processing.
Heidelberglaan 1
Utrecht 3584 CS
NL
Heidelberglaan 1
Utrecht 3584 CS
NL
Listed location countries
Age
Inclusion criteria
healthy, right-handed, age between 18-30, females only using single phase oral contraceptives
Exclusion criteria
- unremovable metal in or around the body
- oversensitivity for OT or carrier
- use of psychotropic medication of recreational drugs
- alcohol use 24 prior to testing
- habitiual smoking
- psychiatric treatment
- neurological treatment
- endocrinological treatment
- history of closed head injury
- history of epilepsy
- claustrophobia
Design
Recruitment
Medical products/devices used
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
EudraCT | EUCTR2008-006002-42-NL |
CCMO | NL25014.041.08 |